“…Further to this observation, multiple experimental approaches based on genetic deletion or pharmacological blockade of NMDARs have uncovered a series of disturbances at the molecular, synaptic, and behavioral level that mimics negative and cognitive symptoms of schizophrenia (Kjaerby et al, 2017; Segev et al, 2020; Seshadri et al, 2018; Wang et al, 2001). For instance, neonatal blockade of NMDARs with the non‐competitive antagonist MK‐801 dysregulates the γ‐aminobutyric acid (GABA)‐ergic transmission of the hippocampus (Ikonomidou et al, 1999; Li et al, 2015) and alters induction and expression of the NMDAR‐dependent, long‐term potentiation of hippocampal area CA1 (Griego, Hernández‐Frausto, et al, 2022; Liu et al, 2009; Yang et al, 2014).…”